Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 3Solid Tumors 2Solid Tumor 2Solid Tumor, Adult 1Relapsed Pediatric Solid Tumor 1Malignant Solid Neoplasm 1HER2-positive 1HER2+ Advanced Breast Cancer 1

Interventions

Specimen Handling 7Interviews as Topic 4Standard of Care 3Practice Guidelines as Topic 3Methods 3Educational Status 3Early Intervention, Educational 3Biopsy 3X-Rays 2Magnetic Resonance Spectroscopy 2veliparib 1trastuzumab biosimilar HLX02 1pertuzumab 1irinotecan sucrosofate 1erdafitinib 1copanlisib 1Verteporfin 1Trastuzumab 1Palliative Care 1PF-05280014 1Ontruzant 1Ogivri 1Iopamidol 1Iohexol 1Health Promotion 1Ferrosoferric Oxide 1Exercise Test 1Carboplatin 1CT-P6 1Asian ginseng 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Neoplasm × Trastuzumab × Other solid neoplasm × Clear all
NCT06136897 2026-04-13

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡